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The  conventional  paradigm  of nonalcoholic  fatty  liver disease  representing  the  “hepatic  manifestation  of
the  metabolic  syndrome”  is outdated.  We  identiﬁed  and  summarized  longitudinal  studies  that,  suppor-
ting  the association  of  nonalcoholic  fatty  liver  disease  with  either  type  2 diabetes  mellitus  or  metabolic
syndrome,  suggest  that  nonalcoholic  fatty  liver  disease  precedes  the  development  of both  conditions.
Online  Medical  databases  were  searched,  relevant  articles  were  identiﬁed,  their  references  were  further
assessed  and tabulated  data  were  checked.
Although several  cross-sectional  studies  linked  nonalcoholic  fatty  liver  disease  to either  diabetes  and
other  components  of  the  metabolic  syndrome,  we focused  on  28 longitudinal  studies  which  provided
evidence  for  nonalcoholic  fatty  liver  disease  as  a risk  factor  for  the  future  development  of  diabetes.
Moreover,  additional  19  longitudinal  reported  that  nonalcoholic  fatty  liver  disease  precedes  and  is a risk
factor  for  the  future  development  of the  metabolic  syndrome.
Finally,  molecular  and  genetic  studies  are  discussed  supporting  the  view  that  aetiology  of  steatosis
and  lipid  intra-hepatocytic  compartmentation  are  a  major  determinant  of  whether  fatty  liver  is/is  not
associated  with  insulin  resistance  and  metabolic  syndrome.
Data support  the  novel  paradigm  of nonalcoholic  fatty  liver  disease  as  a strong  determinant  for  the
development  of  the  metabolic  syndrome,  which  has  potentially  relevant  clinical  implications  for  diag-
nosing,  preventing  and treating  metabolic  syndrome.
©  2014  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  
ND lic. Introduction
Steatosis and steatohepatitis, in the absence of competing aeti-
logies such as high alcohol intake, hepatitis C virus (HCV) infection,
rugs and other endocrine disorders, are both part of the nonalco-
olic fatty liver disease (NAFLD) spectrum [1–3]. NAFLD may  either
ccur in the absence of fatty changes – and is often alluded to either
s “cryptogenic” or nonalcoholic steatohepatitis (NASH)-cirrhosis
4,5] – or encompass hepatic and extra-hepatic complications, from
epatocellular carcinoma to atherosclerosis [6]. NAFLD is presently
Open access under CC BY-NC-ecognized as one the most common causes of altered liver tests,
f end-stage liver disease requiring liver transplantation, and is
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features that comprise the metabolic syndrome [7–9].
The  metabolic syndrome is a cluster of cardio-metabolic condi-
tions, generally triggered by an expansion of the adipose visceral
tissue [10], which include insulin resistance – with or without
impaired glucose metabolism and type 2 diabetes (T2D) – athero-
genic dyslipidemia [low high density lipoprotein (HDL)-cholesterol
and high triglycerides], and high blood pressure [11]. The present
deﬁnition of metabolic syndrome, at variance with one of its earliest
proposals [12], does not include hepatic steatosis despite evidence
supporting this association [13]. The existence and the utility of
metabolic syndrome as a separate entity has been challenged by
some experts [14]. Moreover, it remains controversial whether the
presence of the full-blown syndrome really adds to the cardiovas-
ense.cular risk dictated by its individual components, particularly T2D
[15,16]. Nevertheless, the single traits of the metabolic syndrome
tend to aggregate in the same individuals and, more importantly,
the presence of each of them often anticipates the appearance of
en access under CC BY-NC-ND license.
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Table  1
Nonalcoholic fatty liver disease and metabolic syndrome – the original spectrum of similarities.
Steatosis Metabolic syndrome
Epidemiology
Prevalence in the general population Up to 25% of adults Epidemic in the elderly
Prevalence  grows with age Yes Strongly age-dependent
Males  more affected Yes (adults, children) Yes
Anthropometry
Association with central obesity Abdominal adiposity is an independent predictor Visceral fat is correlated with Insulin response and dyslipidemia
Metabolism  – Association with
Hyperinsulinemia Documented Pathogenic mainstay
Hypertension  In drinkers and non-drinkers Yes
Obesity Yes Yes
Hypertriglyceridemia Yes Yes
Low  HDL Cholesterol Circumstantial Evidence Yes
Clinical features
Systemic disease Yes Yes
Accelerated atherogenesis Circumstantial Evidence Yes
Response to diet and/or exercise In the obese Yes
Experimental pathology
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dapted from Lonardo [20].
dditional components over time [17]. This, together with the pos-
ible progression to organ failure and of the development of some
ancer types, including primary liver cancer [9,11,18,19], makes
etabolic syndrome a relevant condition in clinical practice and a
ajor public health concern worldwide.
In 1999, European researchers [20–22] provided biological, clin-
cal and epidemiological evidence for the theory that NAFLD should
e regarded as the hepatic manifestation of the metabolic syn-
rome (Table 1) [20]. Since then, a “chicken and egg” scientiﬁc
ebate has arisen, concerning the primacy of metabolic syndrome
and insulin resistance) over NAFLD or, conversely, of NAFLD
ver the metabolic syndrome [23]. Moreover, while most studies
cknowledge NAFLD to be a risk factor for T2D [24], the notion that
AFLD anticipates the future development of components of the
etabolic syndrome other than T2D is far less accepted, although
t has been suggested by few authors [23,25,26] mainly based on
heir expert opinion.
In  our systematic review of the literature, we discuss all avail-
ble data supporting the view that NAFLD, rather than being
 mere “manifestation of the metabolic syndrome” is indeed a
ecessary precursor of the future development of metabolic syn-
rome in humans. To this end, further to identifying all relevant
ross-sectional studies, we speciﬁcally address the evidence from
rospective studies showing that NAFLD is an independent risk fac-
or for the future development of both T2D and other components
f the metabolic syndrome. Methodological limitations of such data
re brieﬂy analysed. Finally, we discuss how some examples of
issociation of NAFLD from metabolic syndrome – seemingly con-
radicting our thesis – eventually conﬁrm the general paradigm of
AFLD being a precursor of the metabolic syndrome.
. Research strategy
The  PubMed data base was manually searched for the follow-
ng terms: “Metabolic syndrome”; “Type 2 Diabetes”; “Obesity”;
Dyslipidemia” “Hyperlipidemia”; “Insulin resistance”; “Predictor”;
Fatty liver”; “Follow-up”; “Association” and “Dissociation”. The
esearch was updated at the 28th of April 2014. Further biblio-
raphic updates were performed whenever needed during the
evision process.
All  of the identiﬁed articles and their references were further
hecked in duplicate in order to identify appropriate articles. Per-
inent studies were identiﬁed as a result of the agreement twoHypertensive animals have hyperinsulinemia and hypertriglyceridemia
investigators,  who also tabulated the methods and chief ﬁndings
of the selected material.
The  accuracy of the tabulated data was independently per-
formed by all authors.
3.  Association of NAFLD with other conditions
3.1. Type 2 diabetes
Many  cross-sectional studies demonstrate that NAFLD is asso-
ciated with insulin resistance/pre-diabetes/T2D [27–39]. Despite
a variable follow-up range, data appear consistent in disclosing
that the “NAFLD pathway” to T2D follows a route characterized
by insulin resistance developing at various anatomic sites, notably
including hepatic insulin resistance. Interestingly, the NAFLD-
T2D association occurs irrespective of potential confounders and
particularly obesity and moderate alcohol drinking, suggesting
that NAFLD may  closely mirror the development of fatty pan-
creas disease [40] and thus reﬂect tissue lipotoxicity. Moreover, a
quantitative relationship links fasting plasma glucose with NAFLD
prevalence: the higher the former, the higher the latter [29].
However, widely acknowledged predictors of T2D in non-NAFLD
populations (such as high fasting glucose and low HDL-cholesterol
and adiponectin, mirroring insulin resistance) and low physical
activity also predict T2D in NAFLD suggesting that NAFLD prob-
ably ampliﬁes the physiological determinants of T2D. Finally, most
ﬁndings appear to be conﬁrmed irrespective of ethnicity (e.g.
T2D-prone Asians vs. Caucasians) and of the diagnostic technique
followed to capture NAFLD, spanning from the most invasive or
accurate tests (liver histology, magnetic resonance imaging) to the
most insensitive (liver tests), via the most widely performed ultra-
sonography scanning.
However,  the above studies [27–39] are cross-sectional. Accord-
ingly, they do not rule out the possibility that primarily impaired
gluco-regulation may  eventually result in the development of
NAFLD. In order to clarify this issue, in Supplementary Table S-1
the studies showing NAFLD as a risk factor for the future devel-
opment of T2D were summarized. Eleven out of 12 studies were
conducted in Far East, most of them from Korea. With such a
limitation, they conﬁrm that NAFLD is an independent risk factor
for the development of T2D, although conﬁrmation from Western
countries appears necessary. Moreover, the diagnostic technique
used to detect NAFLD may  lead to different results. For instance,
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Table  2
Nonalcoholic fatty liver disease and metabolic syndrome – the expanded spectrum of similarities.
NAFLD Metabolic syndrome
Increasing serum uric acid levels Are associated with increased prevalence and histological
severity of NAFLD [66–68]
Are  associated with increased prevalence and incidence of
metabolic  syndrome [69–82]
High fructose consumption Is associated with increased prevalence of NAFLD and
increased  NASH severity [83,84] owing to enhanced
lipogenesis, hepatic ﬁbrosis, inﬂammation, endoplasmic
reticulum stress and lipoapoptosis [85]
Increases the risk of developing metabolic syndrome and
its  components [86–88]
TSH Clinical/subclinical hypothyroidism and elevated TSH,
though  in the normal range, are associated with increased
prevalence and histological severity of NAFLD [89–92]
There is a close dose-dependent relationship between
increasing TSH and incident/prevalent metabolic
syndrome in various ethnicities and across different
age-groups [93–97]
Bile acids Participate in the pathogenesis of NAFLD through
regulating hepatic nutrients and energy homeostasis;
stimulating GLP-1 secretion in the small intestine and
energy  expenditure in brown adipose tissue and skeletal
muscle  [98]. UDCA’s role in NASH management, however,
remains  controversial [99,100]
Are  powerful regulators of metabolism and induce
increased thermogenesis, protect from diet induced
obesity, hepatic lipid accumulation, and increased plasma
triglyceride and glucose levels via activation of Bile acids
receptors  (FXR and TGR5) [101–103]
Increased physical exercise Protects from NAFLD, independent of weight loss
[104–108] and improves histological steatosis [109]
Protects from the development of and cures established
metabolic syndrome [110–116]
Light to moderate alcohol consumption Is associated with a reduced prevalence of NAFLD and
NASH  [3,117–120]
Seemingly protects from the development of at least some
components  of the metabolic syndrome. Conversely, heavy
drinking  increases the risk of metabolic syndrome
[121–132]
Caffeine  Seemingly protects from NAFLD and liver ﬁbrosis
[133–136] without decreasing the risk of NASH [134,135].
Beneﬁcial liver outcomes are mediated by antioxidant,
antiﬁbrogenic, antinﬂammatory, insulin sensitizing,
lipolytic, cyto, and genoprotective activity [137–142]
Reported to be a protective factor from metabolic
syndrome, maybe through a lipolytic effects of caffeine on
adipocytes  [143–145].
Smoking  Risk factor for the development of NAFLD and its ﬁbrotic
progression [146–148]
Positively and reversibly associated in a dose-dependent
manner with the risk of metabolic syndrome [149]
Altered sleep physiology Shorter sleep duration and severe obesity-related
obstructive sleep apnoea are independently associated
with  development and histological severity of NAFLD
[150–152]
Altered sleeping time duration and continuity are
associated with increased risk for the metabolic syndrome
[150,153–156]
Brown  adipose tissue Subjects maintaining active brown adipose tissue are
protected  from NAFLD [157]
The  presence of brown adipose tissue is inversely related
to  BMI. Brown adipose tissue activity plays a role in
constitutional leanness without affecting glucose
metabolism [158–161]
Intestinal microbiota May  promote NASH by several mechanisms including
improved energetic efﬁciency; increased gut permeability
and  production of lipopolysaccharides with activation of
the  innate immune system; altered bile acids pool;
reduced bioavailability of dietary choline and increased
endogenous ethanol production [162–172]
Plays a signiﬁcant role in the development of metabolic
syndrome via increased energy harvesting, metabolic
endotoxinemia; control of lipid and glucose metabolism
via  the composition of bile-acid pools and the modulation
of  FXR and TGR5 signalling; modulation of intestinal
microbial composition by innate immune system;
“brain-gut enteric microbiota axis” [170,173–188]
Vitamin  D deﬁciency Is associated with NAFLD development and the severity of
hepatic  histological changes [189–192]
May increase the risk for metabolic syndrome, type 2
diabetes,  insulin resistance, obesity, hypertension and
L on-lik
a d stim
t
a
l
a
s
H
a
i
3
v
[
l
s
t
a
m
tist of abbreviations: BMI, body mass index; FXR, farnesoid X receptor; GLP-1, glucag
titis;  TGR5, membrane-type G-protein-coupled receptor for bile acids; TSH, thyroi
he less speciﬁc gamma-glutamyltransferase (GGT) values more
ccurately predict the development of T2D than aminotransferase
evels. Similarly, the ultrasonographic severity of NAFLD is associ-
ted with increasing risks of T2D and, notably, NASH (more than
imple steatosis) appears to be more closely associated with T2D.
owever, such a conclusion was challenged by a subsequent meta-
nalysis by Musso et al. showing that the risk of developing T2D is
ncreased to a similar extent in both steatosis and NASH [41].
.2.  Other components of metabolic syndrome
Data reporting NAFLD as a risk factor for either some indi-
idual components of metabolic syndrome [arterial hypertension
42,43] and dyslipidemia [44]] or the full-blown syndrome are
ess established than NAFLD progression to T2D. Many cross-
ectional studies support the view that NAFLD is associated with
he metabolic syndrome [13,22,45–64].Data universally conﬁrm the strong NAFLD-metabolic syndrome
ssociation in humans. In addition, although each component of
etabolic syndrome [including serum uric acid, not included in
he diagnostic criteria but clearly a component of the syndromecardiometabolic outcomes [193–198]
e peptide-1; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcholic steatohep-
ulating hormone; UDCA, ursodeoxycholic acid.
from  a pathophysiological point of view [8]] is independently asso-
ciated with NAFLD, a few features (visceral obesity, dyslipidemia
and insulin resistance/T2D) are more closely related to NAFLD.
The association of NAFLD with the metabolic syndrome appears
to be stronger in lean than in obese individuals, especially in
women. NAFLD speciﬁcally anticipates the presence of metabolic
disorders and independently predicts insulin resistance, identify-
ing those individuals with insulin resistance who may  be missed by
metabolic syndrome criteria in certain populations. The frequency
of metabolic syndrome signiﬁcantly increases with quintiles of ALT
and GGT, even within the normal range of these enzymes [51].
Moreover, T2D and hypertriglyceridemia are more commonly asso-
ciated with raised hepato-biliary enzymes, and particularly GGT
[65], an association which appears to be independently mediated
by insulin resistance. In turn, the presence of metabolic syndrome
is associated with the development of ﬁbrosis or NASH.
Again, association in cross-sectional studies does not provide
evidence as to which condition comes ﬁrst. In order to address this
issue, studies supporting the view that NAFLD precedes the devel-
opment of metabolic syndrome are summarized in Supplementary
Table S-2.
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Collectively, they suggest that NAFLD, either diagnosed via sur-
ogate indices or by ultrasonography, antedates the presence of
everal components of metabolic syndrome, not only of T2D. This
ssociation is largely regulated by the presence of insulin resis-
ance. However, in 13 out of 15 such studies, NAFLD was  diagnosed
n surrogate laboratory indices, on ultrasonographic ﬁndings in
wo and in none by the gold standard liver biopsy technique. More-
ver, the diagnostic criteria tended to be heterogeneous and given
hat enlarged waist circumference is both a main pathogenic key
or NAFLD and is central for the diagnosis of metabolic syndrome, it
s virtually impossible to rule out the possibility that visceral obe-
ity links the development of both NAFLD and metabolic syndrome.
inally, no speciﬁc traits of the metabolic syndrome (dysglicemia,
yslipidemia, high blood pressure and central obesity) are manda-
ory for the development of the full-blown metabolic syndrome
Supplementary Table S-2).
. Does NAFLD precede metabolic syndrome? Insulin
esistance as a major player
Compared to our “historical” perception (Table 1), present
nderstanding of the epidemiological, clinical and pathogenic simi-
arities between NAFLD and the metabolic syndrome has expanded
o a substantial extent. Accordingly, it presently embraces a large
umber of risk/protective factors and biological mediators, i.e.,
erum uric acid, fructose, TSH, bile acids, physical exercise, alco-
ol, caffeine, smoking, altered sleep physiology, brown adipose
issue, intestinal microbiota and vitamin D deﬁciency (Table 2)
66–198]. Associations of these factors with NAFLD may  mirror
ifferent pathophysiological mechanisms underlying the natural
ourse leading from NAFLD to metabolic syndrome.
Phylogenetically evolved to promote survival, insulin resistance
ill lead to the deleterious manifestations of the metabolic syn-
rome whenever inappropriately activated by unhealthy lifestyles
199]. Clinically, insulin resistance is deﬁned as the critical
onnector linking stress, visceral adiposity, and decreased cardio-
espiratory ﬁtness with increased cardiovascular disease [14].
iologically, elevated fasting glucose will result from hepatic
nsulin resistance, whereas increased free fatty acids (FFA) con-
entrations are the expression of peripheral insulin resistance
200]. At molecular level, insulin resistance invariably results from
he interaction of cell membrane receptors with either excess
utrients or inﬂammatory cytokines. Such an interaction will
rigger JNK and IKK, protein kinase C, S6K, mTOR, and ERK. All
hese pathways are involved in the ampliﬁcation of inﬂamma-
ion, phosphorylation of insulin receptor substrates 1 and 2, stress
f endoplasmic reticulum, production of reactive oxygen species
nd mitochondrial dysfunction [201]. Once triggered, this vicious
ircle of systemic metabolic dysfunction of insulin and leptin
ction tends to self-perpetuate [202]. Impaired intracellular insulin
ignalling will eventually result in perturbed Glut-4-mediated
lucose uptake with preserved/potentiated MAP  kinase-mediated
itogenesis/cell survival pathways [200].
First proposed, as early as 1988, as the underlying factor in
he metabolic syndrome [203], insulin resistance undoubtedly
lays a major role in the pathophysiology of the metabolic syn-
rome [204]. The expansion of visceral adipose tissue will result
n the liver being overﬂowed with FFA, thus leading to steato-
is. A fatty liver, in turn, is the prerequisite for the development
f highly atherogenic dyslipoproteinemia featuring low HDL-
holesterol, hypertriglyceridemia and increased small and dense
ow-density lipoprotein (LDL) particles, as well as for fasting hyper-
lycemia, which stimulates the pancreas to compensatory insulin
ver-secretion. Collectively, increased FFA concentrations, hyper-
lycemia and hyper-insulinemia may  directly (or indirectly viar Disease 47 (2015) 181–190
sympathetic  over-activation) promote arterial hypertension and
ectopic deposition of fat in extra-adipose tissues. More importantly,
the described metabolic derangements are intimately associated
with increased production of ﬁbrinogen, PAI-1, TNF-alpha, IL-6 and
decreased adiponectin levels. A subclinical pro-inﬂammatory pro-
atherogenic state will ensue, which is a major biological feature of
insulin resistance and a typical hallmark of the metabolic syndrome
[204].
While most individuals with NAFLD have insulin resistance
[13,205], only a minority of those with NAFLD exhibit the full-
blown metabolic syndrome [206]. This ﬁnding most likely results
from fatty liver being a precursor [207] and a necessary prerequisite
to the development of progressive metabolic disease [23,208–210].
Adipose tissue is the only physiologic reservoir of fatty acids, and
the accumulation of fat in the extra-adipose tissues may  be tissue-
damaging and eventually lead to organ dysfunction (a concept
alluded to as “lipotoxicity”). Data from a mouse model support the
view of fatty liver being a protective mechanism which prevents
progressive liver damage in NAFLD [211] suggesting that esteriﬁca-
tion into triglycerides might well be a mechanism which detoxiﬁes
histologically damaging FFA in the liver. Further evidence for the
concept that fatty liver is an adaptive phenomenon derives from its
occurrence in animal species other than humans suggesting that
steatosis is evolutionarily “useful” [212–215].
Characterization of the role of PKC is probably the most exciting
progress in our understanding of the molecular pathogenesis of the
connection linking liver steatosis with hepatic insulin resistance.
In obese humans, fatty substrates such as diacylglycerol account
for 64% of the variability of insulin sensitivity via the activation
of PKC [216], which impairs insulin signalling as shown in rats
using antisense oligonucleotides [217]. Of outstanding interest, the
intracellular compartmentation of diacylglycerol dictates whether
or not PKC will translocate to the plasma membrane so promoting
hepatic insulin resistance [218]. Stated otherwise, various classes of
lipids (such as mono-, di- and tri-acylglycerol) sequestered within
lipid droplets/Endoplasmic reticulum fraction are deemed to be
innocuous as far as the development of hepatic insulin resistance
is concerned in the CGI-58 knockdown mouse model [219].
In  humans, however, most cases of NAFLD are strongly
associated with insulin resistance. In agreement, diacylglycerol
acyltransferase 2 (DGAT2), the enzyme catalysing the ﬁnal step
in the biosynthesis of triglycerides, may  link glycemia and triglyc-
eridemia [220]. These data are fully consistent with the view that
the development of a fatty liver occurs upstream in the chain of
metabolic events eventually leading to the development of the
metabolic syndrome [210] and help understand the mechanistic
reason why subjects with NAFLD were 1.6 times more likely to
develop T2D than NAFLD-free persons in a recent 3-year follow-
up Japanese study [221]. Of clinical interest, a growing number
of components of the metabolic syndrome are associated with an
increased risk of hepatic ﬁbrosis in the individual patient [222]
thus enabling the identiﬁcation of those who should undergo liver
biopsy [223]. In particular, data have shown that a vicious cir-
cle links T2D and liver disease, with NAFLD contributing to the
future development of T2D and the latter triggering progressive
liver injury [40]. Fatty pancreas develops in the setting of metabolic
syndrome, carrying amazing similarities to NAFLD in terms of organ
inﬂammation, end-stage organ failure, susceptibility to cancer and
post-surgical complications [224].
Lipid droplets display a unique protein repertoire including
Adipophilin and TIP47 which, further to fatty adipocytes, are
expressed in lipid droplets of hepatic stellate cells. Perilipin, once
deemed to be characteristic of lipid droplets in the adipocytes and
steroidogenic cells, is expressed de novo in liver cells of steatotic
liver in humans [225]. The ﬁnding that the distribution of perilipin
is predominantly perivenous in the liver lobule [225] may suggest
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Fig. 1. Primacy of nonalcoholic fatty liver disease over metabolic syndrome. Based on epidemiological and biological data discussed in the text, the cartoon schematically
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yndrome, uric acid is deﬁnitely a trait of the metabolic syndrome constellation from
f  nonalcoholic fatty liver disease, as discussed in Table 2. The key-role of lipid drop
ased on recently published data [218,219].
 speciﬁc role of this protein in the four-step model of histoge-
etic events originally proposed by Wanless to account for NASH
athogenesis and its progression to cirrhosis via hepatic venular
bstruction [226]. Perilipin has been conﬁrmed by following stud-
es as one of the most prominent upregulated genes in NAFLD [227].
In summary, alterations in the regulation of lipid droplets phys-
ology and metabolism inﬂuence the risk of developing metabolic
iseases such as T2D and NAFLD [227]. Fig. 1 illustrates the hypoth-
sis that NAFLD is a precursor of the metabolic syndrome via insulin
esistance resulting from PKC activation which conceivably occurs
n most cases of NAFLD in humans.
If the “general rule” is that steatosis and insulin resistance are
ssociated, are there any examples of such two conditions being
issociated from each other?
. Dissociation of NAFLD from insulin resistance and the
etabolic  syndrome
The  ﬁrst clinical evidence for conditions where high-grade
teatosis occurs without insulin resistance or low-grade liver fat
ontent is nonetheless associated with insulin resistance was
eported in 2006. This conclusion was reached by comparing insulin
esistance (assessed by HOMA-IR) and steatosis grade in three nat-
rally occurring different conditions displaying a variable extent
f steatosis: familial hypobetalipoprotenemia (FHBL), NAFLD and
teatosis (evaluated histologically) associated with HCV infection
228]. In 2010 Amaro et al. measuring insulin resistance with the
yperinsulinemic-euglycemic clamp procedure coupled with glu-
ose tracer infusion and liver fat content with magnetic resonance
MR) spectroscopy, conﬁrmed the results in FHBL individuals [229].
f interest, circumstantial evidence suggests that FHBL is associ-
ted with progressive liver disease only in those patients featuring
omponents of the metabolic syndrome [230].
Consistent with the potential occurrence of steatosis dissoci-
ted from insulin resistance, Kantartzis et al. reported that single
ucleotide polymorphisms in the diacylglycerol acyltransferase 2lic syndrome. Although not included in current diagnostic criteria of metabolic
thophysiological point of view and a determinant of development and progression
 potentially protecting fatty liver from developing insulin resistance is highlighted
(DGAT2) gene accounted for variability in liver fat content rather
than for insulin resistance. These results conﬁrm and extend
to humans the ﬁnding that DGAT2 mediates the dissociation
between fatty liver and insulin resistance [231]. The same group
of researchers reported that the patatin-like phospholipase 3 gene
(PNPLA3) is a key factor in determining whether fatty liver is associ-
ated or not with metabolic derangements such as insulin resistance
[232].
Finally, PNPLA3 gene polymorphisms have recently been associ-
ated with those NAFLD cases occurring in the absence of metabolic
syndrome [233], indirectly suggesting that genetic conditions
which promote the development of fatty changes in the liver may
occur independently of insulin resistance.
A detailed survey of those studies demonstrating a dissocia-
tion of fatty liver and T2D in both experimental conditions and
humans has recently been published by Sun et al. [234]. Collec-
tively, ﬁndings from both genetically engineered animal models
and humans with genetic conditions conﬁrm the view that the aeti-
ology of steatosis is a major determinant of whether steatosis is
associated (such as seen in most cases of NAFLD observed in clin-
ical practice) or dissociated from insulin resistance and features
of the metabolic syndrome (such as seen in NAFLD occurring in
carriers of PNPLA3 gene polymorphisms and in FHBL individuals)
[228,233,234]. As schematically depicted in Fig. 1, compartmenta-
tion of intrahepatocytic lipids may  potentially account for the end
result of NAFLD being either associated or dissociated from insulin
resistance [218,219] and therefore from the risk of developing
the metabolic syndrome. Once fully characterized in humans, the
sub-cellular mechanisms of dissociation of steatosis from insulin
resistance may  become a preferential target for the prevention and
management of insulin resistance and the metabolic syndrome.6.  Conclusions
A systematic review of the literature shows that the presence of
NAFLD is intimately linked with the metabolic syndrome, including
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2D. Moreover, NAFLD is a strong determinant for the future devel-
pment of the metabolic syndrome. This is likely to occur as a
esult of its being a key factor associated with insulin resistance
n naturally occurring conditions in humans. Exceptions to such
 theory are found in some genetic polymorphisms where the
teatosis-insulin resistance-metabolic syndrome triad is dissoci-
ted in humans. The molecular biology of events dictating NAFLD
eing associated with or dissociated from insulin resistance is
ncreasingly being elucidated.
On these grounds, the diagnostic importance of NAFLD as a cri-
erion for the presence, as well as for risk of future development
f metabolic syndrome, needs to be emphasized. From a thera-
eutic point of view, those pathogenic-based interventions aimed
t reversing NAFLD are likely to be a rational approach in the
revention and treatment of hepatic insulin resistance, metabolic
yndrome and related complications.
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